← Xenon Pharmaceuticals Inc. (XENE) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Xenon Pharmaceuticals Inc. (XENE)
Pharmaceutical Preparations · market cap $3.6B · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-02 (est.)
Earnings
Pipeline
6
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Xenon Pharmaceuticals (XENE) is a ~$6.7B market cap specialty pharmaceutical company focused on neurological and other ion-channel-mediated disorders, with 316 employees and a cash position of $545.9M. Its two lead late-stage assets are XEN1101 (Phase 3 for Primary Generalized Tonic-Clonic Seizures) and Azetukalner (Phase 3 for Major Depressive Disorder), with a PDUFA date estimated March 2027 for the latter. The company is pre-revenue at scale, burning roughly $300M+ annually in R&D, with an 18-month cash runway and elevated dilution risk.
The catalyst path
- 2026-11-02 (est.)Earningsimp 5/10
- 2027-03-04 (est.)PDUFA · Azetukalnerimp 8/10
- 2027-04-15 (est.)Phase 3 · XEN1101imp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| XEN1101 | Phase 3 | Primary Generalized Tonic-Clonic Seizures |
| Azetukalner | Phase 3 | Major Depressive Disorder |
| XEN1101 10 mg | Phase 2 | Major Depressive Disorder |
| XPF-005 | Phase 2 | Acne Vulgaris |
| XPF-001 | Phase 2 | Dental Pain |
| XPF-002 | Phase 2 | Postherpetic Neuralgia |
Price & technical context
3-month
-38.3%
6-month
-36.0%
12-month
-7.4%
52-wk range
$36.56–$70.96
vs 50-day MA
-35.3%
vs 200-day MA
-30.0%
Realized vol
65.1%
Max drawdown
-48.5%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for XENE (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.